×
ADVERTISEMENT

AUGUST 24, 2017

‘Random’ PCSK9 Coverage Hinders Access

Denver—Despite the ability of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors to reduce cholesterol in patients who are at risk for serious cardiac events, many health plans continue to reject requests for these prescriptions.

If the payor does cover the drug, coverage depends on whether the insurer is a commercial or government payor, further clouding the reimbursement picture, according to the study, which was presented at the 2017 annual meeting of the Academy of